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INTRODUCTION
Myocardial infarcts (MIs) can be especially devastating
when their pathogenesis stems from a coronary artery
occlusion by an intracoronary thrombus (ICT). ICTs are
most frequently a result of an underlying atherosclerotic
plaque rupture, however, can also be a result of emboli,
vasospasm, hypercoagulable states, among other
etiologies. Patients suffering from the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) appear
to be in both a hypercoagulable and proinflammatory
state resulting in an increased risk of clot formation,
endothelial damage, and plaque destabilization, thus
increasing the ICT burden in infected patients.1 The
literature does reflect an increase in ICT ST-segment
elevation myocardial infarction (STEMI) in already high risk
patients with an active SARS-CoV-2 infection. Our case
discusses this observed pathology in a young 24 year old
patient not typically considered among a high risk
population for a ICT STEMI.

CASE PRESENTATION
A 24-year-old male presented to the Emergency Department
with a two-week history of intermittent fevers, anosmia,
ageusia, and shortness of breath. The patient’s nasopharyngeal swab was positive for SARS-CoV-2 by real time
reverse-transcriptase-polymerase-chain-reaction assay.
His vitals on admission were as follows: Blood pressure
was 146/88 mm Hg; heart rate was 127 beats/min, and
respiratory rate was 24 breaths/min. With five liters of
supplemental oxygen therapy his oxygen saturation was
96%. Heart auscultation revealed no murmur. He was in
mild respiratory distress, but able to speak in full sentences
with no accessory muscle use. lung auscultation revealed
coarse bilateral breath sounds with bilateral rales. He was
morbidly obese. Laboratory results were significant for the
following: White blood cell count of 6,700/mL, creatinine
of 2.16 mg/dL, sodium of 127 mmol/l, aminotransferase
of 258 IU/L, alanine aminotransferase of 71 IU/L,creatinine
kinase of 17,732 IU/L, c-reactive protein of 4.3 mg/dL, and
ferritin of 1,224 ng/mL. High-sensitivity troponin T (hs-TnT)
was 24 ng/L on initial presentation and 2 hours later was
19 ng/L (normal <19 ng/L). Electrocardiogram on
presentation was significant for sinus tachycardia and poor
r-wave progression (figure 1).
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The patient underwent treatment for SARS-CoV-2
pneumonia and rhabdomyolysis with five days of
remdesivir, six days of dexamethasone, and intravenous
fluids. On hospital day six the patient no longer required
supplemental oxygen therapy but experienced a three
second pause on telemetry monitoring. The patient left
against-medical-advice and re-presented to the ED within
12 hours complaining of new left-sided chest pain.
Laboratory results were significant for an initial hs-TnT of
217 ng/L and repeat of 415 ng/L. Electrocardiogram was
significant for sinus arrhythmia and acute anterolateral
injury pattern with ST-elevations in leads I, aVL, V3-V6
(figure 2). Chest radiograph was significant for vascular
congestion in bilateral lung fields (figure 3).
Echocardiography was significant for left ventricular
ejection fraction of 40-45%, moderate left ventricular
dysfunction with peri-apical akinesis. The patient
received 324mg of aspirin, 80mg of atorvastatin and
was initiated on intravenous heparin therapy. A transfer
was initiated to a PCI-capable facility.

DIFFERENTIAL DIAGNOSIS
The differential diagnosis included acute ST-elevation
myocardial infarction, pulmonary embolism and
COVID-19 associated myocarditis.

OUTCOME & FOLLOW-UP
The patient was transferred to the cardiac catheterization laboratory for consideration of emergency
coronary angioplasty. Coronary angiogram showed
mid left anterior descending (LAD) artery thrombus
with 50% stenosis and distal LAD thrombus causing
100% occlusion at the apex (figure 4). No intervention
was done as the patient had resolution of his chest
pain. The patient was loaded with 180mg of ticagrelor
and placed on a tirofiban infusion for 24 hours due to
thrombus burden. The patient was maintained on full
dose enoxaparin until discharge due to intracoronary
thrombus burden then subsequently discharged on
dual-antiplatelet therapy, high-intensity statin and
lisinopril. As of a six week follow up the patient has
been chest pain free and doing well.

Figure 1. 12 lead electrocardiogram:
baseline sinus tachycardia.

Figure 2. 12 lead electrocardiogram:
anterolateral ST-segment elevation.

Figure 3. Portable Chest Radiograph: vascular congestion in bilateral lung fields.

Figure 4. Coronary angiogram: mid left anterior descending (LAD) artery
thrombus with 50% stenosis and distal LAD thrombus causing 100% occlusion
at the apex

The Medicine Forum, Volume 22 | 39 5

DISCUSSION

KEY POINTS

Acute coronary syndrome (ACS) events are pharmacologically treated with platelet inhibition using a loading
dose of aspirin, a P2Y12 antagonist, as well as a
continuous heparin drip, titrated to maintain full anticoagulation.2 If the institution’s facilities allow, the patient
will be emergently taken to the cardiac catheterization
lab to assess ICT burden and inter vention via
thrombectomy and angioplasty. Facility capabilities,
clot burden, and the patient’s overall clinical picture
will certainly play a role in management decisions and
which treatments are most appropriate for each
patient. The most appropriate management depends
on patient past medical history, thrombus burden, and
overall goals of care. Early and effective interventions
are associated with better outcomes.

Intracoronary thrombus, COVID-19, Anticoagulation
Management, STEMI

In our case of a young patient positive for SARS-CoV-2
presenting with ACS, the mechanism of how SARS-CoV-2
can affect ICT should be considered as the precipitating
factor and how it may impact our clinical management
decisions. SARS-CoV-2 infections are known to create a
systemic proinflammatory state which appears to also
lead to hypercoagulation and increased thrombus
burden in infected patients.3 An increase in production
of inflammatory markers and cytokines in turn increases
thrombin production and atherosclerotic plaque
instability by increasing the conversion of and fibrinogen
to fibrin in turn activating platelets thereby promoting
clot formation.3 Moreover, in patients that are critically ill
with a SARS-CoV-2 infection can experience dysfunction
in their coagulant concentrations thereby leading to
disordered development of thrombosis and bleeding
called disseminated intravascular coagulation. Sepsis,
tachycardia and systemic inflammation can also
increase coronary blood flow demand precipitating
myocardial ischemia and plaque destabilization.
These proposed mechanisms may have led to our 24
year old patient’s STEMI in the setting of a SARS-CoV-2
infection. There has been an increase in case reports in
the literature on ACS and ICT in SARS-CoV-2 positive
patients.1,3,4,5 Knowing the possible risks of hypercoagulation in SARS-CoV-2, recent studies including the
“IMPROVEDD Score” create risk stratification scores to
determine the need for venous thromboembolism
prophylaxis.6 Similarly, further study is required to guide
prevention and management techniques in ICT in
patients with SARS-CoV-2 infections.
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